Emerging data suggest this peptide, a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , appears to offer a notable step forward for obesity loss . Preliminary clinical investigations have indicated considerable losses in body mass , conceivably surpassing existing weight-loss therapies . Nevertheless , addition